Abstract
Psoriasis is frequently accompanied by cardiovascular diseases based on the shared immunopathogenic pathway. We determined the effect of IL-17 inhibitor therapies on early-stage atherosclerosis related arterial wall inflammation described by intima-media thickness (IMT) among severe psoriatic patients. Thirty-one severe psoriatic patients were enrolled. 20 received secukinumab and 11 received ixekizumab. Before treatment initiation and 6 after months, the carotid-brachial-femoral IMT, the Psoriasis Area Severity Index (PASI) and quality of life scales Dermatology Life Quality of Index (DLQI), EuroQol Visual Analogue Scale (EQ VAS) were evaluated.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
